What is Tesofensine?

Tesofensine is a synthetic small molecule classified as a triple monoamine reuptake inhibitor. Its research targets include the transporters for three chemical messengers: dopamine, norepinephrine (also called noradrenaline), and serotonin. Axel and colleagues, 2010.

What does “reuptake” mean?

Nerve cells release chemical messengers into the small space between cells, called a synapse. Transporter proteins help take those messengers back into cells. Blocking this uptake can increase their availability outside cells and change signalling at nearby receptors.

This transporter action is supported by research. How it translates into eating behaviour involves interacting brain circuits; each messenger cannot be assigned one simple, guaranteed outcome.

Conceptual Graphics: Three Signalling Systems

These illustrations introduce the three systems and their possible interaction. The puzzle pieces and coloured paths are visual metaphors, not anatomical maps or evidence of equal contributions.

Read any appetite, reward or metabolism labels in the artwork alongside the study findings below. Transporter inhibition alone does not establish faster metabolism or reduced enjoyment of food.

What Animal Studies Tell Us About the Mechanism

2010: Testing which receptors contribute

Axel, Mikkelsen and Hansen studied rats with diet-induced obesity. Blocking alpha-1 adrenergic receptors almost reversed tesofensine’s reduction in food intake; blocking dopamine D1 receptors partly reversed it. Blocking the serotonin receptors tested did not reverse that response.

These experiments point to a role for noradrenergic and dopaminergic signalling in that rat model. They do not establish that serotonin has no role under other conditions, or that the three systems contribute equally. Read the receptor study.

2024: Looking inside feeding-related brain circuits

Perez and colleagues studied mice and rats and recorded activity in the lateral hypothalamus, a brain region involved in feeding. Tesofensine inhibited a subset of neurons that use GABA, reducing their ability to promote feeding.

In the rat taste experiments, appetite suppression did not directly change the measured sweetness or palatability of sucrose. This makes “food becomes less rewarding” too simple an explanation. These are animal findings, with translation to humans still requiring evidence. Read the brain-circuit study.

What Has Been Studied in People?

Astrup and colleagues reported a 24-week, placebo-controlled trial in 203 adults with obesity in 2008. Participants also followed an energy-restricted diet. The authors reported greater weight loss with tesofensine, alongside adverse effects including dry mouth, digestive symptoms and insomnia; an increased heart rate was also reported.

Evidence note: The Lancet issued an Expression of Concern about this paper in 2013. Its findings should be read with that notice and should not be presented as settled proof. Read the trial and the journal’s notice.

Human trial observations and animal mechanism experiments answer different questions. A change in body weight does not, by itself, show which brain pathway caused it or prove increased energy expenditure.

Primary Research

• Axel, Mikkelsen and Hansen (2010), Neuropsychopharmacology — alpha-1 and dopamine D1 receptor pathways in rats with diet-induced obesity.
• Perez and colleagues (2024), PLOS ONE — GABAergic hypothalamic neurons and feeding behaviour in mice and rats.
• Astrup and colleagues (2008), The Lancet — a randomised trial of body weight, body composition and quality of life. Read with the 2013 Expression of Concern.